--News Direct--

NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to share news about the beginning of clinical trials for its broad-spectrum antiviral drug NV-CoV-2. This is with two oral drug products NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies.

Diwan told Proactive the Phase 1a/1b safety and efficacy clinical trial began June 17th and is aimed at satisfying the as-yet-unmet medical need for a highly effective broad-spectrum, pan-coronavirus drug that can be used for all patient populations. The trial will use patients with mild to moderate COVID-19 to assess indication of efficacy.

Proactive Investors

+1 604-688-8158

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/nanoviricides-take-big-step-forward-beginning-trials-on-its-antiviral-drug-nv-cov-2-239204407